Mar 2023 Articles

Articles
Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
Nurmohamed NS, Kraaijenhof JM, Mayr M, et al.
Journal:
Eur Heart J

First published: March 29, 2023 DOI: 10.1093/eurheartj/ehad161
View
- Share
Articles
Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study
Fuchs A, Kühl JT, Sigvardsen PE, et al.
Journal:
Ann Intern Med

First published: March 23, 2023 DOI: 10.7326/M22-3027
View
- Share
Articles
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020
Jacobs JA, Addo DK, Zheutlin AR, et al.
Journal:
JAMA Cardiol

First published: March 22, 2023 DOI: 10.1001/jamacardio.2023.0228
View
- Share
Articles
Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial
Ballantyne CM, Banka P, Mendez G, et al.
Journal:
J Am Coll Cardiol

First published: March 6, 2023 DOI: 10.1016/j.jacc.2023.02.018
View
- Share
Articles
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
Ridker PM, Bhatt DL, Pradhan AD, et al.
Journal:
Lancet

First published: March 6, 2023 DOI: 10.1016/S0140-6736(23)00215-5
View
- Share
Articles
PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
Ridker PM, Bhatt DL, Pradhan AD, et al.
Journal:
Lancet

First published: March 6, 2023 DOI: 10.1016/S0140-6736(23)00215-5
View
- Share
Articles
Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease
Virani SS, Ramsey DJ, Westerman D, et al.
Journal:
Circulation

First published: March 5, 2023 DOI: 10.1161/CIRCULATIONAHA.123.064226
View
- Share
Articles
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Schwartz GG, Szarek M, Bhatt DL, et al.
Journal:
Eur Heart J

First published: March 5, 2023 DOI: 10.1093/eurheartj/ehad144
View
- Share
Articles
CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen SE, Lincoff AM, Brennan D, et al.
Journal:
N Engl J Med

First published: March 4, 2023 DOI: 10.1056/NEJMoa2215024
View
- Share
Articles
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial
Zelniker TA, Wiviott SD, Mosenzon O, et al.
Journal:
JAMA Cardiol

First published: March 1, 2023 DOI: 10.1001/jamacardio.2023.0019
View
- Share

Mar 2023 Articles

Articles

Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction

Nurmohamed NS, Kraaijenhof JM, Mayr M, et al.

Articles

Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study

Fuchs A, Kühl JT, Sigvardsen PE, et al.

Articles

Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020

Jacobs JA, Addo DK, Zheutlin AR, et al.

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Articles

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker PM, Bhatt DL, Pradhan AD, et al.

Articles

PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker PM, Bhatt DL, Pradhan AD, et al.

Articles

Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease

Virani SS, Ramsey DJ, Westerman D, et al.

Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

Articles

CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen SE, Lincoff AM, Brennan D, et al.

Articles

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

Zelniker TA, Wiviott SD, Mosenzon O, et al.

Articles

Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction

Nurmohamed NS, Kraaijenhof JM, Mayr M, et al.

Share

Articles

Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study

Fuchs A, Kühl JT, Sigvardsen PE, et al.

Share

Articles

Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020

Jacobs JA, Addo DK, Zheutlin AR, et al.

Share

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Share

Articles

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker PM, Bhatt DL, Pradhan AD, et al.

Share

Articles

PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker PM, Bhatt DL, Pradhan AD, et al.

Share

Articles

Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease

Virani SS, Ramsey DJ, Westerman D, et al.

Share

Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

Share

Articles

CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen SE, Lincoff AM, Brennan D, et al.

Share

Articles

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

Zelniker TA, Wiviott SD, Mosenzon O, et al.

Share